旗濱集團(601636.SH)擬出資6920萬元共同建設中性硼硅藥用玻璃素管項目
格隆匯12月6日丨旗濱集團(601636.SH)公佈，公司擬投資中性硼硅藥用玻璃項目，項目計劃分期建設，建設規模為3窯8線100噸/天(窯爐出料量)中性硼硅藥用玻璃素管，以及產品深加工，項目總投資約6億元。本次擬在湖南省郴州市資興市投資建設第一期中性硼硅藥用玻璃素管項目，本期項目計劃總投資1.55億元，其中自籌資金1億元(本次投資採用跟投機制，公司籌資投入6920萬元，公司事業合夥人等關鍵管理人員共同投資設立的跟投平台跟投認繳3080萬元)，其餘5528萬元申請貸款解決。該項目擬實行跟投管理機制。
參與中性硼硅藥用玻璃素管項目(一期)跟投人員共計101人，其中副總經理級以上的強投人員42人，自願跟投(不含副總經理)人員48人，中性硼硅藥用玻璃素管項目(一期)跟投人員2人，其他符合條件的項目跟投對象8人，外籍(馬來西亞)跟投對象1人。其中參與本項目跟投的董監高人員有董事兼總裁張柏忠、董事長兼董祕姚培武、董事兼財務總監張國明、董事兼副總裁凌根略、董事候英蘭、監事王立勇。
國際中性藥用玻璃即通常所稱的Ⅰ類玻璃，國內也有的稱其為5.0玻璃(該玻璃在20～300℃範圍內平均線性熱膨脹係數α=(4.6～5.8)×10-6K-1的膨脹係數為5.0)或甲級料。這類玻璃以其優異的化學穩定性和熱穩定性在藥品包裝領域得到大量的應用，特別適宜於盛裝生物製品、血液製品、凍乾製劑、疫苗等附加值較高的藥品和PH值較高的特殊藥品。目前，中性硼硅藥用玻璃已經得到國際醫藥包裝市場的廣泛認可(我國和印度等幾個少數國家尚未完全採用)。
根據國際Report linker報告，全球藥用玻璃市場2025年將達到220.5億美元，印度和中國的新興市場的增長率將達到9%，中國將成為藥品玻璃包裝瓶的主要消費國之一。5.0中性玻璃系列產品包括無色和琥珀色玻管，可應用於生產注射器、卡式瓶和筆式系統、安瓿瓶以及西林瓶等的藥品包裝。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
